Core Viewpoint - Furuya Medical Technology (01696) reported a revenue of $165 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 1.9% [1] - The company's net profit attributable to shareholders was $6.426 million, down 41.3% year-on-year, with basic earnings per share at 1.37 cents [1] Group 1: Revenue and Market Conditions - The decline in revenue is primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer spending [1] - Transportation delays in June due to regional tensions also contributed to a slight delay in revenue recognition [1] - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] Group 2: Profitability and Cost Structure - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period [1] - The reduction in gross margin is mainly due to a strategic shift in the product mix towards core professional-grade and precision high-end products, which have higher material costs due to the use of top-tier technology specifications [1] - The decline in revenue contribution from North America also impacted the overall profitability [1] Group 3: Order Backlog - As of June 30, 2025, the order backlog remains robust, increasing by several million dollars compared to the same period in 2024 [1]

格隆汇8月20日丨复锐医疗科技(01696.HK)公告，截至2025年6月30日止6个月，收益为1.66亿美元，较 截至2024年6月30日止6个月收益减少1.9%。经调整纯利为1200万美元，较2024年同期减少28.1%。董事 会议决就截至2025年6月30日止6个月不宣派任何中期股息。 复锐医疗科技业务遍布全球不同区域，结合直销模式，助力快速进入市场并精准触达终端消费者，使北 美以外的市场实现7.1%收益增长。但该增长被北美市场的放缓所抵销，主要由于北美地区持续面对严 峻的宏观经济环境，而且2025年上半年地缘政治紧张局势导致供应链短暂受阻。 ...

Core Viewpoint - Furuya Medical Technology (01696) reported a revenue of $165 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 1.9% [1] - The company's net profit attributable to shareholders decreased by 41.3% to $6.426 million, with basic earnings per share at 1.37 cents [1] Group 1: Revenue and Market Conditions - The decline in revenue is primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer spending [1] - Transportation delays in June due to regional tensions also contributed to a slight delay in revenue recognition [1] - Excluding the adverse factors in the North American market, Furuya Medical Technology's international market achieved a growth of 7.1% compared to the same period in 2024 [1] Group 2: Profitability and Cost Structure - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period [1] - The reduction in gross margin is mainly due to a strategic shift towards core professional-grade and precision high-end products, which have higher material costs due to the use of top-tier technology specifications [1] - The decline in revenue contribution from North America also impacted the overall profitability [1] Group 3: Order Backlog - As of June 30, 2025, the order backlog remains robust, with an increase of several million dollars compared to the same period in 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 截至二零二五年六月三十日止六個月的中期業績公告 財務概要 截至二零二五年六月三十日止六個月： 中期股息 • 董事會議決就截至二零二五年六月三十日止六個月不宣派任何中期股息。 業績概要 復銳醫療科技有限公司*（「本公司」或「復銳醫療科技」）董事會（「董事會」）欣然宣佈本公 司及其附屬公司（統稱「本集團」或「我們」）截至二零二五年六月三十日止六個月（「報告 期」）之未經審核綜合業績連同二零二四年同期的比較數字。該業績乃根據國際財務報告 準則（「國際財務報告準則」）編製。 – 1 – • 收益為165.5百萬美元，較截至二零二四年六月三十日止六個月收益減少1.9%。 • 亞太區收益為65.8百萬美元，較二零二四年同期增長9.9百萬美元，增幅為17.6%。 • 注射填 ...

Company Overview - Foresight Medical Technology (01696.HK) is the first Israeli company listed on the Hong Kong Stock Exchange, established in 2013. Its core subsidiary, Alma, is a leading provider of energy-based surgical and aesthetic medical devices globally [2][3]. - The company is a key platform for Fosun Pharma in the medical aesthetics sector, focusing on creating a consumer-centric ecosystem for beauty and health with a diverse product portfolio and a strong global presence in over 100 countries [2][3]. Financial Performance - As of December 31, 2024, Foresight Medical Technology reported total revenue of 2.51 billion yuan, a year-on-year decrease of 2.83%. The net profit attributable to shareholders was 181 million yuan, down 20.23% year-on-year. The gross profit margin stood at 62.07%, and the debt-to-asset ratio was 22.71% [1]. Market Position and Valuation - The company has a price-to-earnings (P/E) ratio of 15.42, ranking 24th in the healthcare equipment and services industry, where the average P/E ratio is 0.69 and the median is 1.36 [2]. - Other companies in the industry have significantly lower P/E ratios, such as Jingjiu Health (00648.HK) at 0.38 and Giant Medical Holdings (02393.HK) at 0.41, indicating a relatively higher valuation for Foresight Medical Technology [2]. Strategic Goals - The company's objectives extend beyond developing medical-grade beauty and health solutions; it aims to enhance the overall quality of consumers' daily lives and create real value in the health sector. Its multi-layered strategy facilitates cross-marketing of products, providing various cross-brand solutions to business partners, professional clients, and consumers [3]. Upcoming Events - The company is scheduled to disclose its mid-year report for the fiscal year 2025 on August 20, 2025. Additionally, it plans to distribute a final dividend of HKD 0.126 per share for the fiscal year 2024, with the ex-dividend date on August 26, 2025, and the payment date on September 9, 2025 [4].

复锐医疗科技(01696.HK)发布公告，该公司将于2025年9月9日派发末期股息每股0.126港元。 本文源自：金融界AI电报 ...

智通财经APP讯，复锐医疗科技(01696)发布公告，该公司将于2025年9月9日派发末期股息每股0.126港 元。 ...

Core Viewpoint - Furuya Medical Technology (01696) announced that it will distribute a final dividend of HKD 0.126 per share on September 9, 2025 [1] Company Summary - The company is set to pay a final dividend, indicating a commitment to returning value to shareholders [1]

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | | 股票發行人現金股息公告 | | 發行人名稱 | SISRAM MEDICAL LTD 復銳醫療科技有限公司* | | 股份代號 | 01696 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | （更新）截至二零二四年十二月三十一日止年度的末期股息 | | 公告日期 | 2025年8月12日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更新記錄日期及預扣稅率 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.126 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金 ...

（ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 派發二零二四年末期股息的記錄日期及預扣稅率 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* 根據以色列與股東居住國之間的適用稅收協定而有權享有減免稅率但於股息派付 前尚未取得以色列稅務局批准的股東，可以透過向以色列稅務局提交稅務申報（個 人表格1301及公司表格1214）及相關文件（如身份證文件、稅收居民文件、註冊證 書及稅項扣繳的確認）的方式申請退稅。本公司將於派發二零二四年末期股息後向 以 色 列 稅 務 局 申 請 有 關 稅 項 扣 繳 的 確 認 。 股 東 可 通 過 本 公 司 官 網 網 站 www.sisram-medical.com所示的多種溝通渠道聯繫本公司以獲取有關確認的副 本。於稅務申報時，股東須呈報其於以色列所得的所有收入（倘該股東為以色列稅 收居民，其亦須呈報全球範圍內的收入） ...